Creating Value Through Acquisition and Growth
AffaMed Therapeutics is looking for additional opportunities in the biopharma and healthcare market to expand our commercial portfolio. We are committed to addressing the medical needs of underserved patients and the physicians who treat them. With proven experience and a talented management team supported by the financial strength of leading investors, AffaMed is developing therapeutic solutions that create value for patients and stakeholders alike.
Please contact us to discuss possible partnership opportunities.
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. The company were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Its product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives. Ocular Therapeutix intends to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing.
VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets.
Under the management philosophy "contribute to society through high-quality, innovative pharmaceutical products" and "serve society through our employees", Kissei Pharmaceutical Co., Ltd. provides unique innovative pharmaceutical products as a drug discovery and R&D-oriented company for patients in the world with a special focus on urology, renal diseases dialysis, diabetes, gastroenterology and rare diseases.
SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is committed to improve patients' quality of life through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey. Since 2015 SIFI is backed by 21 Invest, a private equity firm founded by Alessandro Benetton.
Beijing Infinite Brain Technologies (IBT) is a leading medical technology company that aims to provide digital curative solutions for central nervous system (CNS) diseases. By leveraging the advanced brain sciences and cutting-edge computational technologies, IBT is committed to improving the process of screening, diagnosis, treatment and management for a wide range of CNS diseases, such as ADHD, autism, schizophrenia, and post stroke cognitive impairment. The company conducts long-term scientific and clinical research, developing and providing proprietary digital therapeutic products that have been clinically validated, by partnering with national key laboratories and top research hospitals in China. Bearing the difficulties of patient and family firmly in mind, IBT strives to level up patient care with products with higher efficacy and lower cost.
Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.
Hanmi Pharm. Co., Ltd. is a Korea-based pharmaceutical company, fully integrated with strong focus in R&D which is strategically designed in 3 major fields: 1) Biologics: LAPSCOVERY platform applied long-acting pipelines. Key targeting areas are diabetes and obesity; 2) NCE: Mainly oncology and auto-immune disease targeted pipelines; and 3) Fixed-dose combination programs. The company has worked closely with global partners on various co-developments and collaborations. Hanmi continues to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.
AskGene (California, USA), founded in 2012 in Los Angeles, California, is dedicated to the discovery and development of novel antibody and fusion protein therapeutics. AskGene is a pioneer in the discovery and development of next generation cytokine therapeutics. It has established the cutting edge SmartKine® cytokine prodrug platform. The SmartKine® platform significantly improves the developability of cytokines for oncology and inflammation indications. AskGene is actively moving multiple projects into clinical and preclinical developments.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen.
